ArticleTurkish journal of biology = Turk biyoloji dergisi2026
Context-dependent regulation of SIX1 by ETS1 within EMT-associated transcriptional networks.
Article in Turkish journal of biology = Turk biyoloji dergisi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/aim: Epithelial-mesenchymal transition (EMT) is a fundamental process driving tumor plasticity, metastasis, and therapy resistance. Although E26 transformation-specific transcription factor 1 (ETS1) and Sine oculis homeobox homolog 1 (SIX1) are individually implicated in EMT-related transcriptional programs, the regulatory interplay and functional coordination of these proteins across tumor states remain unclear. Hence, this study aimed to investigate the mechanistic and clinical behavior of the ETS1-SIX1 axis, with a focus on hepatocellular carcinoma (HCC) and aggressive endothelial-like cancer phenotypes. Materials and methods: ETS1-SIX1 expression patterns were analyzed using real-time quantitative polymerase chain reaction in HCC-derived cell lines and the endothelial-like SK-HEP-1 cell line, whereas chromatin immunoprecipitation (ChIP) assays were performed in SK-HEP-1 cells to assess ETS1 binding to the SIX1 promoter. Clinical relevance was assessed using The Cancer Genome Atlas (TCGA) RNA-sequencing (RNA-seq) datasets (breast invasive carcinoma, colon adenocarcinoma, liver hepatocellular carcinoma (LIHC), and lung adenocarcinoma) with correlation and survival analyses, and validated using tumor cDNA panels and public transcriptomic data. Results: ChIP assays confirmed ETS1 binding to the SIX1 promoter. Expression analyses indicated an inverse relationship between ETS1 and SIX1 in HCC-derived cell lines, the endothelial-like SK-HEP-1 cell line, and tumor cDNA panels. Pan-cancer analyses showed decreased ETS1 and increased SIX1 expression in tumors, with stage-dependent heterogeneity. Elevated SIX1, but not ETS1, was associated with poorer overall survival, particularly in LIHC. Gene set enrichment analysis linked high-risk profiles to EMT, cell cycle, and immune-related pathways, while ETS1 expression decreased with increasing tumor grade. Conclusion: This study supported a model in which ETS1 negatively regulates SIX1 expression within liver cancer-associated contexts. Integrating mechanistic and clinical analyses, the findings suggest that the ETS1-SIX1 axis contributes to EMT-driven tumor plasticity and aggressive tumor behavior, with potential relevance for future therapeutic investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.